Two Checkpoint Inhibitors in One Bispecific Molecule Improved Survival in Patients with High-Risk Gastric Cancer

Audio Journal of Oncology Podcast

An interview with:

Jiafu Ji MD PhD DrPH FRCS, Fellow of the Chinese Academy of Medical Science, Professor and Chief, Gastrointestinal Cancer Center, Peking University Cancer Hospital, Beijing Institute for Cancer Research, Beijing, China

Sarah Maxwell, Audio Journal of Oncology:

The idea of harnessing two different pathways of checkpoint inhibition simultaneously is very appealing for the treatment of high-risk gastric cancers. But a research team in China, proposed that, blocking both the PD-1 and CTLA-4 pathways, within a single bi-specific agent, as a component of initial therapy, was potentially a better way to do this than to use a combination of two individual checkpoint inhibitors.

At the 2024 American Association for Cancer Research annual meeting in San Diego, Jiafu Ji, from the Beijing Institute for Cancer Research, reported his group’s findings from the COMPASSION-15 trial, with 610 patients who had untreated, unresectable, HER2-negative, locally advanced or metastatic gastric cancer, using the bi-specific agent, cadonilimab, together with standard chemotherapy. After his talk he discussed with us the rational for this approach and the promising clinical findings:

Jiafu Ji, MD, PhD, DrPh, State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, the Beijing Key Laboratory of Carcinogenesis and Translational Research, and the Gastrointestinal Cancer Center, Beijing Cancer Hospital, Beijing, China

IN: “Gastric cancer is a leading cause of death in China………

OUT………American Association for Cancer Research, I’m Peter Goodwin”

10:13 secs

AACR ABSTRACT

Cadonilimab plus chemotherapy versus chemotherapy as first-line treatment for unresectable locally advanced or metastatic gastric or gastroesophageal junction (G/GEJ) adenocarcinoma (COMPASSION-15): A randomized, double-blind, phase 3 trial